2025
Characteristics of Children Aged 0 to 23 Months Hospitalized With Respiratory Syncytial Virus.
Wang D, Pham H, Chai S, Hoover C, Armistead I, Kawasaki B, Yousey-Hindes K, Meek J, Witt L, Openo K, Brooks A, Rojewski S, Henderson J, Martin E, Mumm E, Salazar-Sanchez Y, Paloma Shaw Y, Keating F, Rowe A, Popham K, Tesini B, Novak A, Sutton M, Schaffner W, Talbot H, Hill M, Zahid H, Havers F, Patton M. Characteristics of Children Aged 0 to 23 Months Hospitalized With Respiratory Syncytial Virus. 2025, 156 PMID: 40707020, DOI: 10.1542/peds.2024-069719.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusFeeding tube dependenceProlonged ICU admissionICU admissionTube dependenceClinical characteristicsCardiovascular diseaseSyncytial virusAirway abnormalitiesRisk of severe respiratory syncytial virusAssociated with airway abnormalitiesSevere respiratory syncytial virusRespiratory syncytial virus seasonHospitalized childrenChildren aged 8RSV-associated hospitalizationsPopulation-based surveillance systemAged 0Down syndromeChildren Aged 0Aged 8Aged 0 to 2Severe diseaseChildren 3Months
2024
Evaluation of Immunoglobulin A Enzyme Immunoassays to Detect Primary Respiratory Syncytial Virus Infection in Infants and Young Children
Sankaranarayanan R, Ha B, Sun H, Liu K, Jadhao S, Hussaini L, McCracken C, Gibson T, Yildirim I, Yi J, Stephens K, Korski C, Kao C, Rostad C, Anderson E, Anderson L. Evaluation of Immunoglobulin A Enzyme Immunoassays to Detect Primary Respiratory Syncytial Virus Infection in Infants and Young Children. The Journal Of Infectious Diseases 2024, 231: 1060-1068. PMID: 39575588, PMCID: PMC12168064, DOI: 10.1093/infdis/jiae514.Peer-Reviewed Original ResearchRespiratory syncytial virus infectionRespiratory syncytial virusIgA enzyme immunoassayRespiratory syncytial virus seasonDocumented RSV infectionPlasma specimensEnzyme immunoassayRSV infectionRSV-FRespiratory syncytial virus antibodiesGroup DRespiratory syncytial virus FCord blood specimensGroup C specimensAcute lower respiratory infectionGroup B specimensPresence of maternal antibodiesLower respiratory infectionsImmunoglobulin G antibodiesRSV antibodiesNegative control groupSyncytial virusAntibody enzyme immunoassayRespiratory infectionsGroup BNonadjuvanted Bivalent Respiratory Syncytial Virus Vaccination and Perinatal Outcomes
Son M, Riley L, Staniczenko A, Cron J, Yen S, Thomas C, Sholle E, Osborne L, Lipkind H. Nonadjuvanted Bivalent Respiratory Syncytial Virus Vaccination and Perinatal Outcomes. JAMA Network Open 2024, 7: e2419268. PMID: 38976271, PMCID: PMC11231799, DOI: 10.1001/jamanetworkopen.2024.19268.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusNeonatal intensive care unitPreterm birthWeeks gestationRisk of HDPPerinatal outcomesLogistic regression modelsIncreased riskPregnant individualsPrenatal vaccinationSmall-for-gestational age birth weightNeonatal intensive care unit admissionCohort studyIncreased risk of PTBOdds ratioIncreased risk of HDPRisk of preterm birthRespiratory syncytial virus seasonRespiratory syncytial virus vaccineRetrospective observational cohort studyNeonatal respiratory distressVaccination statusMultivariate logistic regression modelObservational cohort studyCox regression modelsAcute Cardiac Events in Hospitalized Older Adults With Respiratory Syncytial Virus Infection
Woodruff R, Melgar M, Pham H, Sperling L, Loustalot F, Kirley P, Austin E, Yousey-Hindes K, Openo K, Ryan P, Brown C, Lynfield R, Davis S, Barney G, Tesini B, Sutton M, Talbot H, Zahid H, Kim L, Havers F, Rowlands J, Spina N, Engesser K, Salazar-Sanchez Y, George A, Staten H, Bleecker M, Leegwater L, Tellez Nunez V, Falkowski A, Felsen C, Licherdell E, St George K, Pacheco F, Desiato J, Labozzo N, Zmek E, Alden N, Strayhorn N, Fawcett E, Surell C, Como-Sabetti K, Mumm E, Bilski K, Markus T, Ndi D, Billings K. Acute Cardiac Events in Hospitalized Older Adults With Respiratory Syncytial Virus Infection. JAMA Internal Medicine 2024, 184: 602-611. PMID: 38619857, PMCID: PMC11019447, DOI: 10.1001/jamainternmed.2024.0212.Peer-Reviewed Original ResearchRespiratory syncytial virus infectionRespiratory syncytial virusRespiratory syncytial virus seasonAcute cardiac eventsCardiac eventsWeighted estimated prevalenceIn-Hospital DeathAdjusted risk ratiosIntensive care unitClassification of diseasesCross-sectional studyHospitalized adultsCardiac complicationsRSV infectionRSV diseaseLaboratory-confirmed RSV infectionOlder adultsCases of RSV infectionReceipt of invasive mechanical ventilationCardiovascular diseaseIntensive care unit admissionSevere outcomesEstimated prevalenceAcute heart failurePotential cardiac complicationsThe impact of undergoing elective pediatric lung resection during respiratory syncytial virus peak season on patient outcomes: A nationwide retrospective analysis
Salvi P, Canner J, Coons B, Cowles R, Engwall‐Gill A, Kunisaki S, Penikis A, Schneider E, Sferra S, Solomon D. The impact of undergoing elective pediatric lung resection during respiratory syncytial virus peak season on patient outcomes: A nationwide retrospective analysis. Pediatric Pulmonology 2024, 59: 1346-1353. PMID: 38353176, DOI: 10.1002/ppul.26914.Peer-Reviewed Original ResearchRespiratory syncytial virus seasonCongenital lung malformationsRespiratory syncytial virusPediatric Health Information SystemPostoperative mechanical ventilationLung resectionHospital billing chargesLung surgeryViral seasonMechanical ventilationAssociated with adverse surgical outcomesCLM patientsRSV incidencePediatric Health Information System dataCenters for Disease Control dataRetrospective observational cohort studyElective lung resectionPediatric lung resectionsPediatric thoracic surgeryElective lung surgeryTime of surgeryAdverse surgical outcomesObservational cohort studyIncreased utilization of healthcare resourcesUtilization of healthcare resourcesImproving Palivizumab Administration to High-Risk Infants with Heart Disease via a Communication-Based Quality Improvement Initiative
Leone D, Rodriguez A, Cowenhoven K, O’Connell M, Grossman M, Ferdman D. Improving Palivizumab Administration to High-Risk Infants with Heart Disease via a Communication-Based Quality Improvement Initiative. Pediatric Cardiology 2024, 46: 287-295. PMID: 38300318, DOI: 10.1007/s00246-023-03388-3.Peer-Reviewed Original ResearchHigh-risk infantsPercentage of infantsRate of administrationPalivizumab administrationPalivizumab dosesRespiratory syncytial virus seasonHeart diseaseDose of palivizumabCongenital heart diseasePediatric cardiac patientsPalivizumab eligibilityEligible infantsPalivizumab treatmentVirus seasonPalivizumabHeart CenterCardiac patientsInfantsOxygen saturationDoseDiagnosis codesQuality improvement initiativesAdministrationBaseline rateMultidisciplinary teamDevelopment and comparison of immunologic assays to detect primary RSV infections in infants
Anderson L, Jadhao S, Hussaini L, Ha B, McCracken C, Gibson T, Yildirim I, Yi J, Stephens K, Korski C, Kao C, Sun H, Lee C, Jaunarajs A, Rostad C, Anderson E. Development and comparison of immunologic assays to detect primary RSV infections in infants. Frontiers In Immunology 2024, 14: 1332772. PMID: 38283339, PMCID: PMC10811012, DOI: 10.3389/fimmu.2023.1332772.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusIgG enzyme immunoassayNeutralizing antibody assaysELISPOT assayAntibody assayRSV antibodiesEnzyme immunoassayRSV infectionSubgroup ARespiratory syncytial virus seasonDocumented RSV infectionPrimary RSV infectionEffective respiratory syncytial virusVaccine clinical trialsEvidence of past infectionEpidemiological studiesRed cell lysisYoung childrenMaternal microchimerismPBMC specimensPregnant womenIFN-gSyncytial virusAntibody enzyme immunoassayELISPOT
2010
Burden of respiratory syncytial virus in hospitalized infants and young children in Amman, Jordan
Khuri-Bulos N, Williams JV, Shehabi AA, Faouri S, Al Jundi E, Abushariah O, Chen Q, Ali SA, Vermund S, Halasa NB. Burden of respiratory syncytial virus in hospitalized infants and young children in Amman, Jordan. Infectious Diseases 2010, 42: 368-374. PMID: 20100116, PMCID: PMC2854220, DOI: 10.3109/00365540903496544.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsCost of IllnessFemaleHospitalizationHumansInfantJordanLength of StayMaleMiddle EastNosePharynxPrevalenceProspective StudiesRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus, HumanReverse Transcriptase Polymerase Chain ReactionRNA, ViralSex FactorsUnited StatesConceptsAcute respiratory infectionsMedian ageNose/throat swabsRespiratory syncytial virus seasonChildren's median ageRSV-negative childrenRSV-positive childrenSpecific viral causeLonger hospital stayHigher hospital chargesIntensive care unitRespiratory syncytial virusReal-time polymerase chain reactionLower median ageEffective preventive measuresJordanian infantsHospital stayHospitalized infantsRSV vaccineRespiratory infectionsCare unitHospital chargesSyncytial virusThroat swabsViral cause
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply